Adding an immune drug to standard treatment for new brain lymphoma
Original title: R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This study lists no phase, and it is still a test in people rather than care your own doctor can give.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests whether adding a drug called penpulimab helps people with a lymphoma that starts in the brain.
Who this trial is for. This trial is for people with primary CNS lymphoma, a lymphoma of the brain and spinal cord, who have not been treated for it yet. It compares the usual drug mix, rituximab, methotrexate, and cytarabine, with that same mix plus a drug called penpulimab.
Where it stands. The trial has not reported results. It is measuring how many people go 2 years without the cancer growing. Nobody knows yet which group does better.
What this means, and what it doesn't
What it could mean: If this sounds like your situation, you could ask your care team about it. They can tell you whether looking into this trial makes sense for you. Your team decides what fits your case.
What it doesn't mean: This does not mean the added drug works. A trial is a test, not a proven treatment. Joining one is not a promise that you will do better. And it is not a promise of a cure.
Source: ClinicalTrials.gov, August 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.